ESMO 2021 – the jury remains out on CDK7 inhibition

Two tiny biotechs, Syros Pharmaceuticals and Carrick Therapeutics, are hoping that a twist on cyclin-dependent kinase inhibition can help them overcome resistance to front-line breast cancer therapy. However, just unveiled abstracts covering upcoming Esmo presentations on their first clinical studies show glimmers of efficacy at best.